Loading...
Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. The last earnings update was 11 days ago. More info.
7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
---|---|---|---|---|---|---|
Dr. Lal PathLabs (LALPATHLAB) | 1.9% | -1.7% | 16.5% | 13.6% | 20.8% | - |
IN Healthcare | 0.5% | -7.3% | -2.3% | -13.3% | -14.6% | 35.4% |
IN Market | -2.1% | -4.5% | -3.5% | -8.6% | 40.3% | 78.7% |
Below are the data sources, inputs and calculation used to determine the intrinsic value for Dr. Lal PathLabs.
Data Point | Source | Value |
---|---|---|
Valuation Model | 2 Stage Free Cash Flow to Equity | |
Levered Free Cash Flow | Average of 15 Analyst Estimates (S&P Global) | See below |
Discount Rate (Cost of Equity) | See below | 13.5% |
Perpetual Growth Rate | 10-Year IN Government Bond Rate | 7.6% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
Data Point | Calculation/ Source | Result |
---|---|---|
Risk-Free Rate | 10-Year IN Govt Bond Rate | 7.6% |
Equity Risk Premium | S&P Global | 7.5% |
Healthcare Unlevered Beta | Simply Wall St/ S&P Global | 0.46 |
Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.462 (1 + (1- 35%) (0%)) |
0.462 |
Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.8 |
Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 7.55% + (0.8 * 7.45%) |
13.51% |
Discounted Cash Flow Calculation for NSEI:LALPATHLAB using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Dr. Lal PathLabs is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.
2019 | 2020 | 2021 | 2022 | 2023 | |
Levered FCF (INR, Millions) | 1,770.50 | 2,095.33 | 2,637.88 | 3,271.00 | 3,668.00 |
Source | Analyst x8 | Analyst x9 | Analyst x8 | Analyst x1 | Analyst x1 |
Present Value Discounted (@ 13.51%) |
1,559.77 | 1,626.24 | 1,803.65 | 1,970.35 | 1,946.52 |
Present value of next 5 years cash flows | ₹8,906.54 |
Calculation | Result | |
---|---|---|
Terminal Value |
= FCF2023
× (1 + g) ÷ (Discount Rate – g)
= ₹3,668.00 × (1 + 7.55%) ÷ (13.51% – 7.55%) |
₹66,190.17 |
Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)5
= ₹66,190.17 ÷ (1 + 13.51%)5 |
₹35,125.53 |
Calculation | Result | |
---|---|---|
Total Equity Value |
= Present value of next 5 years cash flows +
Terminal Value
= ₹8,906.54 + ₹35,125.53 |
₹44,032.06 |
Equity Value per Share (INR) |
= Total value / Shares Outstanding
= ₹44,032.06 / 83.34 |
₹528.61 |
Calculation | Result | |
---|---|---|
Non-primary Listing Adjustment Factor |
1 share in NSEI:LALPATHLAB
represents 1.00053x
of
BSE:539524
(This could be a different class, a depositary receipt, a different currency, or all of these things.) |
1.00053x |
Value per Share (Listing Adjusted, INR) |
= Value per Share (INR) x Listing Adjustment Factor
= ₹ 528.33 x 1.00053 |
₹528.61 |
Value per share (INR) | From above. | ₹528.61 |
Current discount | Discount to share price of
₹1,029.05
= -1 x (₹1,029.05 - ₹528.61) / ₹528.61 |
-94.7% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Data Point | Source | Value |
---|---|---|
Earnings Per Share * | Company Filings (2018-12-31) in INR | ₹23.36 |
BSE:539524 Share Price ** | BSE (2019-02-19) in INR | ₹1028.5 |
India Healthcare Industry PE Ratio | Median Figure of 23 Publicly-Listed Healthcare Companies | 24.56x |
India Market PE Ratio | Median Figure of 2,715 Publicly-Listed Companies | 15.16x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Dr. Lal PathLabs.
Calculation | Outcome | |
---|---|---|
PE Ratio | = BSE:539524 Share Price ÷ EPS (both in INR) = 1028.5 ÷ 23.36 |
44.03x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Data Point | Source | Value |
---|---|---|
PE Ratio | See PE Ratio Section | 44.03x |
Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts |
19.2%per year |
Asia Healthcare Industry PEG Ratio | Median Figure of 13 Publicly-Listed Healthcare Companies | 1.85x |
India Market PEG Ratio | Median Figure of 606 Publicly-Listed Companies | 1.1x |
*Line of best fit is calculated by linear regression .
Calculation | Outcome | |
---|---|---|
PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 44.03x ÷ 19.2% |
2.3x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Data Point | Source | Value |
---|---|---|
Book Value per Share | Company Filings (2018-12-31) in INR | ₹106.12 |
BSE:539524 Share Price * | BSE (2019-02-19) in INR | ₹1028.5 |
India Healthcare Industry PB Ratio | Median Figure of 32 Publicly-Listed Healthcare Companies | 1.92x |
India Market PB Ratio | Median Figure of 3,587 Publicly-Listed Companies | 1.04x |
Calculation | Outcome | |
---|---|---|
PB Ratio | = BSE:539524 Share Price ÷ Book Value per Share (both in INR) = 1028.5 ÷ 106.12 |
9.69x |
* Primary Listing of Dr. Lal PathLabs.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Data Point | Source | Value (per year) |
---|---|---|
NSEI:LALPATHLAB Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts | 19.2% |
NSEI:LALPATHLAB Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 15 Analysts | 13.6% |
India Healthcare Industry Earnings Growth Rate | Market Cap Weighted Average | 42.7% |
India Healthcare Industry Revenue Growth Rate | Market Cap Weighted Average | 13.2% |
India Market Earnings Growth Rate | Market Cap Weighted Average | 18.5% |
India Market Revenue Growth Rate | Market Cap Weighted Average | 11.7% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Data Point | Source | Value |
---|---|---|
Past Financials | Company Filings (1 month ago) | See Below |
Future Estimates | Average of up to 15 Analyst Estimates (S&P Global) | See Below |
Date (Data in INR Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
---|---|---|---|---|
2023-03-31 | 20,980 | 4,018 | 1 | |
2022-03-31 | 18,323 | 3,571 | 1 | |
2021-03-31 | 16,306 | 2,918 | 2,920 | 14 |
2020-03-31 | 14,112 | 2,502 | 2,447 | 15 |
2019-03-31 | 12,137 | 2,121 | 2,025 | 15 |
Date (Data in INR Millions) | Revenue | Cash Flow | Net Income * |
---|---|---|---|
2018-12-31 | 11,691 | 1,923 | |
2018-09-30 | 11,393 | 1,825 | |
2018-06-30 | 10,999 | 1,761 | |
2018-03-31 | 10,569 | 1,971 | 1,708 |
2017-12-31 | 10,100 | 1,617 | |
2017-09-30 | 9,548 | 1,565 | |
2017-06-30 | 9,389 | 1,586 | |
2017-03-31 | 9,124 | 1,713 | 1,546 |
2016-12-31 | 8,902 | 1,576 | |
2016-09-30 | 8,713 | 1,876 | |
2016-06-30 | 8,249 | 1,413 | |
2016-03-31 | 7,913 | 1,585 | 1,322 |
*GAAP earnings excluding extraordinary items.
Data Point | Source | Value |
---|---|---|
Past Financials | Company Filings (1 month ago) | See Below |
Future Estimates | Average of up to 15 Analyst Estimates (S&P Global) | See Below |
All data from Dr. Lal PathLabs Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
Date (Data in INR Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
---|---|---|---|---|
2023-03-31 | ||||
2022-03-31 | ||||
2021-03-31 | 35.07 | 40.00 | 30.30 | 12.00 |
2020-03-31 | 29.38 | 31.70 | 26.55 | 13.00 |
2019-03-31 | 24.31 | 26.20 | 22.47 | 13.00 |
Date (Data in INR Millions) | EPS * |
---|---|
2018-12-31 | 23.36 |
2018-09-30 | 22.20 |
2018-06-30 | 21.45 |
2018-03-31 | 20.85 |
2017-12-31 | 19.49 |
2017-09-30 | 18.88 |
2017-06-30 | 19.15 |
2017-03-31 | 19.02 |
2016-12-31 | 19.05 |
2016-09-30 | 20.34 |
2016-06-30 | 15.85 |
2016-03-31 | 16.09 |
*GAAP earnings excluding extraordinary items.
How has Dr. Lal PathLabs performed over the past 5 years?
All data from Dr. Lal PathLabs Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
Date (Data in INR Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
---|---|---|---|---|
2018-12-31 | 11,691.18 | 1,922.65 | 2,293.77 | |
2018-09-30 | 11,393.18 | 1,824.65 | 2,237.77 | |
2018-06-30 | 10,999.18 | 1,760.65 | 2,172.77 | |
2018-03-31 | 10,569.18 | 1,707.65 | 2,101.77 | |
2017-12-31 | 10,099.83 | 1,617.05 | 898.00 | |
2017-09-30 | 9,547.83 | 1,565.05 | 808.00 | |
2017-06-30 | 9,388.83 | 1,586.05 | 752.00 | |
2017-03-31 | 9,123.83 | 1,545.88 | 1,693.70 | |
2016-12-31 | 8,901.88 | 1,576.50 | 700.38 | |
2016-09-30 | 8,713.08 | 1,875.90 | 675.88 | |
2016-06-30 | 8,248.58 | 1,412.70 | 625.28 | |
2016-03-31 | 7,913.18 | 1,321.90 | 580.28 | |
2015-12-31 | 7,654.30 | 1,201.37 | 2,151.57 | 11.15 |
2015-03-31 | 6,595.90 | 907.67 | 497.25 | |
2014-03-31 | 5,579.47 | 762.71 | 1,755.40 | 9.54 |
2013-03-31 | 4,516.61 | 521.28 | 1,443.59 | 11.45 |
2012-03-31 | 3,422.07 | 397.43 | 1,107.99 | 14.75 |
*GAAP earnings excluding extraordinary items.
How is Dr. Lal PathLabs's financial health and their level of debt?
All data from Dr. Lal PathLabs Company Filings, last reported 1 month ago.
Date (Data in INR Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
---|---|---|---|
2018-12-31 | 8,781.00 | 0.00 | 6,505.00 |
2018-09-30 | 8,781.00 | 0.00 | 6,505.00 |
2018-06-30 | 7,949.70 | 0.00 | 4,551.99 |
2018-03-31 | 7,949.70 | 0.00 | 4,551.99 |
2017-12-31 | 6,848.00 | 0.00 | 4,414.00 |
2017-09-30 | 6,848.00 | 0.00 | 4,414.00 |
2017-06-30 | 6,621.92 | 0.00 | 3,428.88 |
2017-03-31 | 5,979.57 | 0.00 | 3,397.16 |
2016-12-31 | 6,105.40 | 0.00 | 3,449.70 |
2016-09-30 | 6,105.40 | 0.00 | 3,449.70 |
2016-06-30 | 5,102.38 | 0.00 | 2,939.68 |
2016-03-31 | 5,102.38 | 0.00 | 2,742.74 |
2015-12-31 | |||
2015-03-31 | 3,433.76 | 0.00 | 1,861.02 |
2014-03-31 | 2,333.33 | 16.03 | 1,142.52 |
2013-03-31 | 1,636.73 | 12.28 | 762.34 |
2012-03-31 | 1,170.73 | 4.16 | 182.13 |
What is Dr. Lal PathLabs's current dividend yield, its reliability and sustainability?
Data Point | Source | Value |
---|---|---|
Past Annualized Dividend Yield | S&P Global Market Data | See Below |
Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
Future Dividends per Share Estimates | Average of up to 15 Analyst Estimates (S&P Global) | See Below |
India Healthcare Industry Average Dividend Yield | Market Cap Weighted Average of 9 Stocks | 0.7% |
India Market Average Dividend Yield | Market Cap Weighted Average of 1397 Stocks | 1.4% |
India Minimum Threshold Dividend Yield | 10th Percentile | 0.3% |
India Bottom 25% Dividend Yield | 25th Percentile | 0.6% |
India Top 25% Dividend Yield | 75th Percentile | 2.1% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
Date (Data in ₹) | Dividend per Share (annual) | Avg. No. Analysts |
---|---|---|
2023-03-31 | ||
2022-03-31 | ||
2021-03-31 | 5.42 | 9.00 |
2020-03-31 | 4.93 | 10.00 |
2019-03-31 | 4.53 | 9.00 |
Date (Data in ₹) | Dividend per share (annual) | Avg. Yield (%) |
---|---|---|
2018-11-29 | 5.500 | 0.561 |
2018-05-14 | 4.500 | 0.490 |
2017-11-09 | 3.200 | 0.364 |
2017-05-12 | 3.400 | 0.413 |
2017-02-02 | 2.600 | 0.268 |
2016-07-29 | 2.450 | 0.227 |
2016-05-30 | 2.450 | 0.262 |
2016-02-15 | 0.000 | 0.000 |
2015-12-23 | 0.000 | 0.000 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Dr. Om Prakash Manchanda, also known as Om, has been the Chief Executive Officer of Dr. Lal PathLabs Pvt. Ltd. since April 01, 2008 and has been its Whole Time Director since February 01, 2011. He has a diverse experience of over 24 years across sales, marketing and general management functions in business sectors such as FMCG, agri-biotech products, consumer healthcare and medical diagnostics. Dr. Manchanda served as the Chief Operating Officer of Dr. Lal PathLabs Pvt. Ltd. He joined Dr Lal PathLabs in 2005. He led the International & Innovation group of the Consumer Healthcare Division at Ranbaxy. He was part of the senior management team responsible for launching Ranbaxy’s foray into consumer healthcare. Prior to Ranbaxy, he worked at Monsanto as the head of Sales and Marketing, where his team successfully launched the company’s first ever biotech product Bt-Cotton. He served at Hindustan Unilever for about 10 years. He received in-depth exposure in consumer product sales, distribution and marketing. He cherishes the memory of how at Unilever, as the Senior Brand Manager - Innovation, he had led the designing and launching of a tea-based beverage at HLL, which won Unilever's Global Innovation Award. Dr. Manchanda considers that award special among the several awards he had received at Unilever. He has been an Independent Director at Prataap Snacks Limited since July 05, 2016. He is an avid reader of management books with his favorite authors being Steven Covey, Jack Welch, Peter M Senge and John Philip Jones. He has an MBA from the Indian Institute of Management, Ahmadabad. Dr. Manchanda is also a Doctor in Veterinary Sciences from HAU, Hisar. Dr. Manchanda holds a bachelor's degree in veterinary science and animal husbandry Agricultural University from the Haryana Agricultural University and a post graduate diploma in management (agriculture) from the Indian Institute of Management, Ahmadabad.
Average tenure and age of the Dr. Lal PathLabs management team in years:
Average tenure and age of the Dr. Lal PathLabs board of directors in years:
Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (₹) | Value (₹) | |
---|---|---|---|---|---|---|---|---|---|---|
15. Feb 19 | Sell | Munender Soperna | Individual | 11. Feb 19 | 13. Feb 19 | -2,975 | ₹1,040.88 | ₹-3,096,611 | ||
15. Feb 19 | Buy | Munender Soperna | Individual | 13. Feb 19 | 13. Feb 19 | 50 | ₹1,026.85 | ₹51,342 | ||
05. Dec 18 | Sell | Neelum Tripathi | Individual | 03. Dec 18 | 03. Dec 18 | -2,000 | ₹878.78 | ₹-1,757,551 | ||
24. Sep 18 | Sell | Shankha Banerjee | Individual | 29. Aug 18 | 29. Aug 18 | -500 | ₹1,114.00 | ₹-557,000 | ||
31. Aug 18 | Sell | Neelum Tripathi | Individual | 29. Aug 18 | 29. Aug 18 | -1,500 | ₹1,100.91 | ₹-1,651,372 | ||
29. Aug 18 | Sell | Shankha Banerjee | Individual | 24. Aug 18 | 27. Aug 18 | -3,000 | ₹1,046.77 | ₹-3,140,308 | ||
29. Aug 18 | Sell | Manoj Garg | Individual | 27. Aug 18 | 27. Aug 18 | -1,500 | ₹1,060.00 | ₹-1,590,000 | ||
23. Aug 18 | Sell | Bharath Uppiliappan | Individual | 17. Aug 18 | 17. Aug 18 | -200 | ₹1,004.00 | ₹-200,800 | ||
23. Aug 18 | Sell | Shankha Banerjee | Individual | 17. Aug 18 | 21. Aug 18 | -1,500 | ₹1,025.33 | ₹-1,538,000 | ||
04. Jul 18 | Sell | Manoj Garg | Individual | 25. Jun 18 | 29. Jun 18 | -1,500 | ₹957.97 | ₹-1,436,950 | ||
02. Jul 18 | Sell | Shankha Banerjee | Individual | 28. Jun 18 | 29. Jun 18 | -1,500 | ₹940.00 | ₹-1,410,000 | ||
29. Jun 18 | Sell | Neelum Tripathi | Individual | 28. Jun 18 | 28. Jun 18 | -2,000 | ₹930.01 | ₹-1,860,022 | ||
25. Jun 18 | Sell | Dilip Bidani | Individual | 21. May 18 | 22. Jun 18 | -3,000 | ₹910.33 | ₹-2,731,000 | ||
20. Jun 18 | Sell | Om Manchanda | Individual | 18. Jun 18 | 18. Jun 18 | -100,000 | ₹863.01 | ₹-86,300,716 | ||
31. May 18 | Sell | Om Manchanda | Individual | 29. May 18 | 31. May 18 | -28,070 | ₹866.94 | ₹-24,335,071 | ||
18. May 18 | Buy | C. A. Ved Goel | Individual | 14. May 18 | 14. May 18 | 8,866 | ₹110.80 | ₹982,353 | ||
22. Feb 18 | Sell | Lal Pathlabs Pvt. Ltd, Employees Welfare Trust | Company | 19. Feb 18 | 21. Feb 18 | -121,000 | ₹909.21 | ₹-109,925,977 | ||
22. Feb 18 | Sell | Shankha Banerjee | Individual | 28. Dec 17 | 29. Dec 17 | -300 | ₹895.89 | ₹-268,767 | ||
05. Mar 18 | Sell | Dilip Bidani | Individual | 27. Feb 18 | 28. Feb 18 | -1,200 | ₹911.17 | ₹-1,093,400 |
It's quite normal to see company insiders, such as board members, trading in company stock, from time to time. … In the last twelve months, the biggest single sale by an insider was when CEO & Whole Time Director Om Manchanda sold ₹86m worth of shares at a price of ₹863 per share. … As a general rule we consider it to be discouraging when insiders are selling below the current price
Simply Wall St - – Full articleHelp shape the future of investing tools and you could win a $250 gift card! … Building up an investment case requires looking at a stock holistically. … Lal PathLabs Limited (NSE:LALPATHLAB) due to its excellent fundamentals in more than one area.
Simply Wall St - – Full articleGenerally speaking, as a company grows, institutions will increase their ownership. … As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'. … Our analysis of the ownership of the company, below, shows that.
Simply Wall St - – Full articleLal PathLabs’s cash flow health and the risk-return concept based on the stock’s cash flow yield, using the most recent financial data. … This will help you think about the company from a cash perspective, which is a crucial factor to investing. … Free cash flow (FCF) is the amount of cash Dr
Simply Wall St - – Full articleThis report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … Lal PathLabs Limited has a market capitalization of ₹80b, and pays its CEO total annual compensation worth ₹30m. … We looked at a group of companies with market capitalizations from ₹28b to ₹112b, and the median CEO compensation was ₹24m.
Simply Wall St - – Full articleWhile some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … Lal PathLabs has a return on equity of 21% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleYour equity share is granted in return for the capital provided to the business to operate, and in order for an investment to be successful the business has to create earnings from the funds that make up this capital. … You need to pay attention to this because your return on investment is linked to dividends and internal investments to improve the business, which can only occur if the company is expected to produce adequate earnings with the capital that has been provided. … Lal PathLabs, you need to look at what the company returns to owners for the use of their capital, which can be done in many ways but today we will use return on capital employed (ROCE).
Simply Wall St - – Full articleThis article is written for those who want to get better at using price to earnings ratios (P/E ratios). … Lal PathLabs has a price to earnings ratio of 38.2, based on the last twelve months. … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)
Simply Wall St - – Full articleDr Lal PathLabs Limited (NSE:LALPATHLAB) is considered a high growth stock. … However its last closing price of ₹895.5 left investors wondering whether this growth has already been factored into the share price. … Lal PathLabs is poised for extremely high earnings growth in the near future
Simply Wall St - – Full articleand want to learn about Return on Equity using a real-life example. … If LALPATHLAB borrows debt to invest in its business, its profits will be higher. … But ROE does not capture any debt, so we only see high profits and low equity, which is great on the surface.
Simply Wall St - – Full article
Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. It operates laboratories for carrying the pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The company offers a range of diagnostic and related healthcare tests and services for use in core testing and patient diagnosis, as well as in the prevention, monitoring, and treatment of disease and other health conditions. Its customers include individual patients, hospitals, other healthcare providers, and corporate customers. As of May 14, 2018, the company owned and operated a National Reference Laboratory in New Delhi, as well as 191 other clinical laboratories, 2,153 patient service centers, and approximately 5,624 pickup points. Dr. Lal PathLabs Limited was founded in 1949 and is based in Gurgaon, India.
Name: | Dr. Lal PathLabs Limited |
LALPATHLAB | |
Exchange: | NSEI |
Founded: | 1949 |
₹85,754,349,609 | |
83,341,610 | |
Website: | http://www.lalpathlabs.com |
Address: |
Dr. Lal PathLabs Limited Tower B, SAS Tower, 12th Floor, Gurgaon, Haryana, 122001, India |
Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
---|---|---|---|---|---|---|---|
BSE | 539524 | Equity Shares | Mumbai Stock Exchange | IN | INR | 23. Dec 2015 | |
NSEI | LALPATHLAB | Equity Shares | National Stock Exchange of India | IN | INR | 23. Dec 2015 |
Health Care Services | |
Healthcare |
Area | Date (UTC time) |
---|---|
Company Analysis updated: | 2019/02/19 13:32 |
End of day share price update: | 2019/02/19 00:00 |
Last estimates confirmation: | 2019/02/12 |
Last earnings filing: | 2019/02/08 |
Last earnings reported: | 2018/12/31 |
Last annual earnings reported: | 2018/03/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.